ABOUT US
Our
Story
Founded in 2019, Topmunnity Therapeutics integrates a team of experts in biotechnology, pharmaceutical development and artificial intelligence to revolutionize disease treatment.
Topmunnity is advancing two pipeline products: an antibody-drug conjugate (ADC) TT-01 ADC, and a chimeric antigen receptor T-Cell therapy CAR-108.
Through AI-drivened antibody modeling and cheminformatics-based molecular dynamics, we accelerate the development of innovative functional antibodies, offering novel therapeutic possibilities for cancer and other complex diseases, reshaping the future of medicine.
Our Mission
Life is invaluable. By harnessing innovative technologies to treat diseases, extend lifespan, and enhance quality of life, we unlock the true value of science and technology.
